知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.025 秒)

    Nutritional formulations
    2.
    发明申请
    Nutritional formulations 审中-公开
    营养配方

    公开(公告)号：US20020044961A1

    公开(公告)日：2002-04-18

    申请号：US09972664

    申请日：2001-10-09

    申请人： DrugTech Corporation

    发明人： Mitchell I. Kirschner ,  R. Saul Levinson ,  Marc S. Hermelin

    IPC分类号： A61K009/64

    CPC分类号： A61K33/26 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/44 ,  A61K31/505 ,  A61K31/519 ,  A61K45/06 ,  A61K33/06 ,  A61K2300/00

    摘要： This invention relates to novel dosage formulations for nutritional compositions comprising fatty acids derived from both plant and animal sources and methods for minimizing unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, nausea, or difficulty in swallowing or ingesting nutritional agents. The nutritional compositions are intended for use by pregnant or lactating women.

    摘要翻译： 本发明涉及用于营养组合物的新型剂型，其包含源自植物和动物来源的脂肪酸和用于最小化不愉快味道，反胃，胃食管反流，消化不良，恶心或吞咽或摄入营养剂困难的方法。 营养组合物是供怀孕或哺乳期妇女使用的。

    ENDOMETRIOSIS TREATMENT
    5.
    发明申请
    ENDOMETRIOSIS TREATMENT 审中-公开
    内分泌治疗

    公开(公告)号：US20130184245A1

    公开(公告)日：2013-07-18

    申请号：US13733213

    申请日：2013-01-03

    申请人： DRUGTECH CORPORATION

    发明人： Daniel J. Thompson ,  Robert C. Cuca ,  Thomas C. Riley ,  Jonathan David Bortz

    IPC分类号： A61K9/00 ,  A61K31/58

    CPC分类号： A61K9/0034 ,  A61K9/06 ,  A61K31/58

    摘要： A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.

    摘要翻译： 药物组合物包含至少一种非脂性内相和至少一种与阴道粘膜表面生物粘附的脂质外部相，并且包含按组合物重量计约3％至约30％的量的达那唑，其中在应用 组合物对阴道粘膜表面达那唑在约1至约10天的时间内释放。 组合物可用于阴道内给药以治疗诸如表达达那唑的子宫内膜异位症的病症。

    Means for creating a mass having structural integrity
    9.
    发明申请
    Means for creating a mass having structural integrity 审中-公开

    公开(公告)号：US20030021842A1

    公开(公告)日：2003-01-30

    申请号：US10245639

    申请日：2002-09-18

    申请人： DRUGTECH CORPORATION

    发明人： Yury Lagoviyer ,  R. Saul Levinson ,  Denis Stotler ,  Thomas C. Riley

    IPC分类号： A61K009/20

    CPC分类号： A61K9/0056 ,  A61K9/1623 ,  A61K9/1658 ,  A61K9/2081 ,  Y10S514/96 ,  Y10S514/961

    摘要： The present invention relates to a means for creating a mass having structural integrity, including a rapidly disintegratable tablet for administration with or without the use of water. The present invention has a wide variety of different uses and applications. One embodiment is a tablet intended for oral administration. The tablet comprises at least one active ingredient and a mixture of excipients. The excipients provide desired characteristics and physical properties and when the tablet is sintered or heated, excellent tablet binding characteristics are obtained. The tablet is intended primarily for oral administration and dissolves in the presence of water. Also disclosed is a process for the preparation of a rapidly disintegratable tablet for administration with or without the use of water. The process comprising dissolving at least one bulking agent and at least one structural agent in a suitable solvent, wherein the solvent provides high porosity upon drying; spray-drying or dispersing said dissolved mixture to obtain a bead or granulated product; dry blending at least one binding agent, and at least one active ingredient with the bead or granulated product to obtain a preformulation product or adding at least one active ingredient to the preformulation product dissolved or dispersed components before spray-drying or dispersing; compressing the preformulation product; and sintering or heating the preformulation product for a sufficient time and temperature to allow the binding agent to change status or melt and allow the binding agent to resolidify as the temperature is reduced to ambient temperature.